These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 1591421)
1. Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis. King JH; Kailath EJ; Hrdy DB Ann Pharmacother; 1992 May; 26(5):639-41. PubMed ID: 1591421 [TBL] [Abstract][Full Text] [Related]
2. Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Fichtenbaum CJ; Smith MJ Clin Infect Dis; 1992 Jan; 14(1):353-4. PubMed ID: 1571451 [TBL] [Abstract][Full Text] [Related]
3. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741 [TBL] [Abstract][Full Text] [Related]
4. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Erasmo AA; Crisostomo AC; Yan LN; Hong YS; Lee KU; Lo CM Asian J Surg; 2004 Jul; 27(3):227-35. PubMed ID: 15564167 [TBL] [Abstract][Full Text] [Related]
6. Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008. Reyes MP; Ali A; Mendes RE; Biedenbach DJ Medicine (Baltimore); 2009 Sep; 88(5):294-301. PubMed ID: 19745688 [TBL] [Abstract][Full Text] [Related]
7. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775 [TBL] [Abstract][Full Text] [Related]
8. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Uhari M; Seppänen J; Heikkinen E Pediatr Infect Dis J; 1992 Jun; 11(6):445-50. PubMed ID: 1608680 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371 [TBL] [Abstract][Full Text] [Related]
13. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Solomkin JS; Dellinger EP; Christou NV; Busuttil RW Ann Surg; 1990 Nov; 212(5):581-91. PubMed ID: 2241313 [TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology]. Derevianko II; Nefedova LA; Lavrinova LN Urologiia; 2002; (3):21-5. PubMed ID: 12180053 [TBL] [Abstract][Full Text] [Related]
15. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Basoli A; Meli EZ; Mazzocchi P; Speranza V Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041 [TBL] [Abstract][Full Text] [Related]
16. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia. Zilberberg MD; Mody SH; Chen J; Shorr AF Surg Infect (Larchmt); 2010 Oct; 11(5):409-17. PubMed ID: 20666580 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of the imipenem/cilastatin combination in the therapy of severe infections in patients with malignant diseases. Cristiano P; Iovene MR; Simioli F; Pezza M; Raucci G; Lobello R Drugs Exp Clin Res; 1990; 16(6):293-7. PubMed ID: 2086164 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Ong CT; Kuti JL; Nicolau DP; Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Kotapati S; Kuti JL; Nicolau DP Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]